Viridian Therapeutics appoints Christopher Cain to board; Peter Harwin resigns effective March 10

Viridian Therapeutics, Inc.\DE

Christopher Cain (Director of Research, Fairmount Funds Management) named Class I director and chair of Nominating and Corporate Governance Committee.
Peter Harwin resigned from the board effective March 10, 2025, with no disagreement with the company.
Cain also joins the Audit Committee and Science & Technology Committee; standard director compensation applies.
Cain previously served at Samsara BioCapital, Apple Tree Partners, RA Capital Management, and BioCentury.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Peter Harwin

Director

VRDN · Viridian Therapeutics, Inc.\DE

Effective: 2025-03-10
Filed: March 10, 2025, 7:59 PM ET

On March 5, 2025, Peter Harwin, a member of the Board, notified the Company of his decision to resign as a member of the Board effective as of March 10, 2025.

Appointed

Christopher Cain

Class I Director

VRDN · Viridian Therapeutics, Inc.\DE

Effective: 2025-03-10
Filed: March 10, 2025, 7:59 PM ET

appointed Christopher Cain, Ph.D., the Director of Research at Fairmount Funds Management LLC, to serve as a Class I director of the Company, chairperson of the Nominating and Corporate Governance Committee, and member of the Audit Committee and Science & Technology Committee, effective as of March 10, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Harwin resigned as Director at Viridian Therapeutics, Inc.\DE.

Action: resigned
Role: Director

Exact text from the filing

On March 5, 2025, Peter Harwin, a member of the Board, notified the Company of his decision to resign as a member of the Board effective as of March 10, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Cain was appointed as Class I Director at Viridian Therapeutics, Inc.\DE.

Action: appointed
Role: Class I Director

Exact text from the filing

appointed Christopher Cain, Ph.D., the Director of Research at Fairmount Funds Management LLC, to serve as a Class I director of the Company, chairperson of the Nominating and Corporate Governance Committee, and member of the Audit Committee and Science & Technology Committee, effective as of March 10, 2025.

View on SEC.gov

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-25-050880

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.